var data={"title":"Beta agonists in asthma: Acute administration and prophylactic use","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Beta agonists in asthma: Acute administration and prophylactic use</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/contributors\" class=\"contributor contributor_credentials\">Robert F Lemanske, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/contributors\" class=\"contributor contributor_credentials\">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 01, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beta adrenergic drugs are the most potent bronchodilators currently approved for clinical use in asthma and obstructive lung disease. Among the beta agonists, the individual agents vary in their rapidity of onset and duration of action. Inhaled, short-acting, selective beta-2 adrenergic agonists are the mainstay of acute asthma therapy, while inhaled, long-acting, selective beta-2 adrenergic agonists (in combination with inhaled glucocorticoids) play a role in long-term control of moderate to severe asthma [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The mechanism of action of beta adrenergic medications and their clinical use in the management of asthma will be reviewed here. The general approach to asthma management, the treatment of acute exacerbations of asthma, and an overview of the delivery of inhaled medications are discussed separately. (See <a href=\"topic.htm?path=an-overview-of-asthma-management\" class=\"medical medical_review\">&quot;An overview of asthma management&quot;</a> and <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults#H14\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;, section on 'Inhaled beta agonists'</a> and <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-adults\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beta agonists were developed through modifications of the <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> molecule to allow selective interaction with the beta-1 and beta-2 receptors (eg, <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a>), rather than the combined alpha and beta effects of epinephrine. Further modification allows selectivity for beta-2 receptors on bronchial smooth muscle to achieve bronchodilation without the tachycardia associated with activation of beta-1 receptors on cardiac muscle. Agents available by inhalation that are selective for the beta-2 adrenergic receptor (eg, <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>, <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a>, <a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">formoterol</a>) are preferred for asthma therapy compared with nonbeta-2 selective agents (eg, <a href=\"topic.htm?path=metaproterenol-orciprenaline-drug-information\" class=\"drug drug_general\">metaproterenol</a>), because they provide equivalent bronchodilation with less cardiac stimulation [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2\" class=\"abstract_t\">2</a>]. Isoproterenol, a nonselective beta agonist, is no longer used to treat asthma exacerbations, due to the better safety and duration of action profiles of other available medications.</p><p>The beta-2 receptor is a G protein-coupled transmembrane receptor that activates the enzyme adenylyl cyclase [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/3\" class=\"abstract_t\">3</a>]. Activation of adenylyl cyclase produces cyclic adenosine monophosphate (cAMP). The exact mechanism by which cAMP causes smooth muscle relaxation is not fully understood, but likely involves activation of protein kinase A and changes in intracellular calcium concentrations. Activation of the beta-2 receptor also affects potassium channels through a separate mechanism. The function of the beta-2 adrenergic receptor and the role of polymorphisms of the receptor in individual responses to beta agonists are discussed separately. (See <a href=\"topic.htm?path=beta-2-adrenergic-receptor-dysfunction-and-polymorphism-in-asthma\" class=\"medical medical_review\">&quot;Beta-2 adrenergic receptor dysfunction and polymorphism in asthma&quot;</a>.)</p><p>Variations in the molecular structure of beta agonists affect the onset and duration of bronchodilation. As an example, prolongation of the bronchodilator effect (relative to <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a>) is achieved by modifications that reduce susceptibility to degradation by catechol O-methyl transferase (COMT) and monoamine oxidase [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2\" class=\"abstract_t\">2</a>]. In addition, the long, lipophilic side chains of <a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">formoterol</a> and <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a> attach to the plasma membrane and increase the duration of binding of the drugs to the adrenergic receptor. The lipophilic side chain of salmeterol leads to incorporation of the drug into the cell membrane and activation of the beta adrenergic receptor through an alternate binding site, rather than the usual site in the aqueous surface of the cell membrane [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/3\" class=\"abstract_t\">3</a>]. It is thought that accessing the alternate binding site deeper in the cell membrane slows the onset of action of salmeterol. In contrast, formoterol has a different lipophilic side chain and its onset of action is comparable to that of <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> (also known as salbutamol).</p><p>Chronic daily use of beta agonists as monotherapy to relieve symptoms may result in the paradoxical situation in which symptom control becomes progressively more difficult to achieve. One possible mechanism for this effect is down-regulation of the number of beta-2 adrenergic receptors on the cell surface [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2,3\" class=\"abstract_t\">2,3</a>]. (See <a href=\"#H12\" class=\"local\">'Tolerance'</a> below and <a href=\"topic.htm?path=beta-2-adrenergic-receptor-dysfunction-and-polymorphism-in-asthma#H3\" class=\"medical medical_review\">&quot;Beta-2 adrenergic receptor dysfunction and polymorphism in asthma&quot;, section on 'Receptor dysfunction in asthma'</a>.)</p><p>Beta-2 agonists also interact with beta adrenergic receptors on the surface of a variety of other cells that play a role in asthma pathogenesis. As examples, beta agonists have the potential to decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2,4\" class=\"abstract_t\">2,4</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-asthma\" class=\"medical medical_review\">&quot;Pathogenesis of asthma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">USE IN ACUTE EXACERBATIONS OF ASTHMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short-acting beta-2 agonists (SABAs) are the drug of choice for acute treatment of asthma symptoms and exacerbations [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p class=\"headingAnchor\" id=\"H2109930\"><span class=\"h2\">Heterogeneity of response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The individual response to beta agonist therapy for an acute exacerbation of asthma is related to many factors, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The relative contribution of bronchoconstriction versus airway inflammation and edema in producing the underlying airway obstruction; bronchoconstriction is usually more responsive whereas the other components are not</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Route of medication delivery (oral, inhaled, parenteral) (see <a href=\"#H4\" class=\"local\">'Importance of route of delivery'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The triggering mechanism (exercise, allergen exposure, infection)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concurrent medication and beta agonist use </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age, since airway geometry and the ability to utilize various delivery systems are important factors in children</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of symptoms; a longer duration of symptoms (eg, days rather than minutes) typically suggests concomitant airway inflammation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The outcome measure(s) used to evaluate the response, both subjective (eg, ease of breathing) and objective (eg, improvements in peak flow or spirometry)</p><p/><p>Some patients with asthma exacerbations appear to require substantially higher doses of beta agonists to achieve reversal of bronchoconstriction [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/7,8\" class=\"abstract_t\">7,8</a>]. This relative resistance may reflect one of the above factors, or beta receptor downregulation due to the disease itself or to chronic beta agonist overuse [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2\" class=\"abstract_t\">2</a>]. Thus, repetitive or continuous administration of a SABA is often needed for patients with moderate to severe exacerbations [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5,6\" class=\"abstract_t\">5,6</a>]. As the dose of SABA increases, the risk of toxicity and need for appropriate monitoring also increases (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). The management of acute exacerbations of asthma is discussed separately. (See <a href=\"#H179762302\" class=\"local\">'Toxicity'</a> below and <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults#H13\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;, section on 'Treatment in emergency department or urgent care setting'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Importance of route of delivery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The route of delivery (eg, metered dose inhaler, nebulized, oral, subcutaneous, intravenous) of the beta agonist is another determinant of efficacy. It might be expected that oral or parenteral administration would be more effective than inhaled use, since mucous plugging might prevent adequate airway penetration of inhaled forms. However, studies evaluating the relative efficacy have shown that inhaled and subcutaneous routes are superior to oral therapy, but consensus as to whether the inhaled or subcutaneous route is superior has not been reached. (See <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-adults\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in adults&quot;</a> and <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-children\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in children&quot;</a> and <a href=\"topic.htm?path=use-of-medication-nebulizers-in-children\" class=\"medical medical_review\">&quot;Use of medication nebulizers in children&quot;</a> and <a href=\"topic.htm?path=the-use-of-inhaler-devices-in-children\" class=\"medical medical_review\">&quot;The use of inhaler devices in children&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Many patients comment that the subjective clinical benefit observed following nebulized therapy is superior to that following metered dose inhalation; however, objective data using equal drug dosages generally do not support these claims [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/9,10\" class=\"abstract_t\">9,10</a>]. On the other hand, nebulizer therapy would be preferred for patients who are unable to cooperate effectively with use of a metered dose inhaler (MDI) because of their age, agitation, or severity of exacerbation [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher doses of oral beta agonists are required to achieve a bronchodilator response comparable to inhaled preparations, due to poor absorption and rapid gastrointestinal metabolism [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2\" class=\"abstract_t\">2</a>]. Further, the therapeutic effect is delayed; peak bronchodilation does not occur until two hours after ingestion [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/11\" class=\"abstract_t\">11</a>], making oral administration appropriate only for mild to moderate asthmatic symptoms and perhaps in patients unable to use other delivery methods due to age or lack of immediate availability.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Variable results have been obtained when inhaled and parenteral delivery routes are compared. In one study, for example, repeated inhalations of nebulized <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a> (2.5 mg) produced more bronchodilation than subcutaneous <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> (0.3 mg) in acute asthma; each drug was given three times at 20 minute intervals [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/12\" class=\"abstract_t\">12</a>]. On the other hand, some patients who are initially refractory to a nebulized beta agonist may respond to subcutaneous epinephrine with peak flow rates increasing by 120 <span class=\"nowrap\">L/min</span> and both peak flow rates and FEV<sub>1</sub> increasing by 20 percent or more above baseline [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Comparisons of nebulized or intravenous administration of individual beta-2 agonists have also been performed. While early evaluations suggested some advantages with intravenous administration [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/14\" class=\"abstract_t\">14</a>], subsequent studies with both <a href=\"topic.htm?path=terbutaline-drug-information\" class=\"drug drug_general\">terbutaline</a> [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/15\" class=\"abstract_t\">15</a>] and <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/16\" class=\"abstract_t\">16</a>] have demonstrated equivalent or superior effects on pulmonary function with nebulized inhalation therapy [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/17\" class=\"abstract_t\">17</a>]. In a meta-analysis on the use of intravenous beta agonist therapy for acute asthma that compared the outcomes of 584 patients in 15 trials, intravenous therapy was not associated with improved outcomes in the study population or any identified subgroup [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/18\" class=\"abstract_t\">18</a>]. Intravenous administration of beta agonists is clearly associated with the development of more adverse effects [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/15,16,19\" class=\"abstract_t\">15,16,19</a>].</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Levalbuterol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">Albuterol</a> is a racemic mixture with a 1:1 ratio of the isomers R-albuterol (<a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>) and S-albuterol; the R-isomer is responsible for the drug's bronchodilating activity. The approval of the R-isomer of albuterol, levalbuterol, has led to controversy about whether it is superior to racemic albuterol as a bronchodilator in asthma [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/20-22\" class=\"abstract_t\">20-22</a>]. While some investigators have concluded that levalbuterol has a better therapeutic ratio (fewer systemic effects for the same degree of bronchodilation) than albuterol [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/21,23-25\" class=\"abstract_t\">21,23-25</a>], others have not been able to support these findings [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/26\" class=\"abstract_t\">26</a>]. Overall, levalbuterol appears to have no clinically significant advantage over racemic albuterol [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/20,27-30\" class=\"abstract_t\">20,27-30</a>].</p><p>Data in children treated in an emergency department setting [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/26,31\" class=\"abstract_t\">26,31</a>] and in adults hospitalized with exacerbations of both asthma and COPD [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/26,32\" class=\"abstract_t\">26,32</a>] have demonstrated that <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a> may reduce hospital admission rates (children) and reduce overall costs if the patient is hospitalized (adults). Conversely, other published results in children given levalbuterol in the emergency department setting do not support any advantage over racemic <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> in a number of outcome measures, including hospitalization [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/29,33\" class=\"abstract_t\">29,33</a>]. </p><p>It is hypothesized that the S-isomer of <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> activates pro-constrictive and pro-inflammatory pathways in bronchial smooth muscle cells [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/34\" class=\"abstract_t\">34</a>]. These effects would theoretically diminish the beneficial effects of the R-isomer (<a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>), although the clinical importance of these detrimental effects is unclear [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Until the results of additional comparison trials with racemic <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> have been published, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a> use should be reserved for those patients who have a known history of adverse effects from albuterol.</p><p class=\"headingAnchor\" id=\"H1487481\"><span class=\"h2\">Use as rescue medication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short-acting beta agonists (eg, <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>) in MDIs are the first line of therapy for the quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness) (<a href=\"image.htm?imageKey=PULM%2F72467\" class=\"graphic graphic_table graphicRef72467 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5,6\" class=\"abstract_t\">5,6</a>]. SABAs are prescribed for use as-needed, rather than on a routine basis.</p><p><a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">Formoterol</a>, a long-acting beta agonist (LABA) has an acute onset of action in the same time frame as <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/35,36\" class=\"abstract_t\">35,36</a>]. However, formoterol is not approved for quick relief of asthma symptoms due to insufficient data [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Escalating use of a SABA (&gt;6 to 8 puffs per day from a metered dose inhaler or use exceeding one canister per month) is a warning sign that the patient's underlying disease activity is inadequately controlled and that additional intervention is warranted (<a href=\"image.htm?imageKey=PULM%2F53233\" class=\"graphic graphic_table graphicRef53233 \">table 3</a> and <a href=\"image.htm?imageKey=PULM%2F78322\" class=\"graphic graphic_table graphicRef78322 \">table 4</a> and <a href=\"image.htm?imageKey=PULM%2F64986\" class=\"graphic graphic_table graphicRef64986 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=an-overview-of-asthma-management#H999003370\" class=\"medical medical_review\">&quot;An overview of asthma management&quot;, section on 'Adjusting medication in patients already on controller therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H2109923\"><span class=\"h2\">Use in emergency department</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, the response of patients with acute exacerbations of asthma to beta agonist therapy is not uniformly predictable. Nevertheless, a few initial guidelines can be proposed for asthmatic exacerbations severe enough to require presentation to the emergency department. Preparations of both inhaled and systemic beta-agonists, delivery systems, and dosing guidelines are listed in the table (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). The other aspects of treatment of asthma exacerbations are discussed separately. (See <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the patient can demonstrate proper MDI technique, two to six inhalations of a SABA (such as <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> or <a href=\"topic.htm?path=terbutaline-drug-information\" class=\"drug drug_general\">terbutaline</a>) can be administered using a spacer or chamber device (eg, AeroChamber, InspirEase) (<a href=\"image.htm?imageKey=PULM%2F58957\" class=\"graphic graphic_picture graphicRef58957 \">picture 1</a>). Therapy can be repeated in 30 to 60 minutes until maximal improvement in pulmonary function can be demonstrated. (See <a href=\"topic.htm?path=the-use-of-inhaler-devices-in-adults\" class=\"medical medical_review\">&quot;The use of inhaler devices in adults&quot;</a> and <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-children\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in children&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alternatively, if the patient is unable to use the MDI, does not exhibit a satisfactory clinical response, or if the <span class=\"nowrap\">patient/providers</span> prefer nebulizer treatment, the SABA is administered by nebulizer. Doses of SABAs for nebulization are provided in the table (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). Within the range of doses, the higher doses and continuous nebulization are used for more severe exacerbations. However, the cumulative dose should be monitored because of the potential adverse effects, and should not exceed the recommended limits listed in the table. (See <a href=\"#H2109930\" class=\"local\">'Heterogeneity of response'</a> above and <a href=\"#H179762302\" class=\"local\">'Toxicity'</a> below and <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-adults#H10617078\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in adults&quot;, section on 'Continuous nebulization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SABAs may be mixed with <a href=\"topic.htm?path=ipratropium-drug-information\" class=\"drug drug_general\">ipratropium</a> for the initial management (first three hours) of severe exacerbations [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults#H16\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;, section on 'Inhaled anticholinergics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rarely, <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> (0.01 <span class=\"nowrap\">mg/kg</span> to a maximum dose of 0.3 to 0.5 mg) is administered subcutaneously or intramuscularly, if nebulized therapy is either unavailable or ineffective clinically (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous beta agonist therapy, particularly with <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a>, is not recommended, since it has been associated with adverse cardiac effects [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2,19\" class=\"abstract_t\">2,19</a>]. (See <a href=\"#H4\" class=\"local\">'Importance of route of delivery'</a> above and <a href=\"#H179762302\" class=\"local\">'Toxicity'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta agonist therapy is associated with a decrease in arterial oxygen tension (PaO<sub>2</sub>) of 5 mmHg or more, so supplemental oxygen is provided to maintain the pulse oxygen saturation above 90 percent (above 95 percent in pregnant women and patients with coexistent cardiac disease), for severe exacerbations, or when continuous measurement of pulse oximetry is not available [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">&quot;Pulse oximetry&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PROPHYLAXIS IN ALLERGEN-INDUCED ASTHMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In IgE sensitized patients, relevant allergen exposure can elicit both an immediate (within minutes) bronchoconstrictive response and a late (hours) inflammatory response, which is often accompanied by recurrent bronchoconstriction. (See <a href=\"topic.htm?path=pathogenesis-of-asthma\" class=\"medical medical_review\">&quot;Pathogenesis of asthma&quot;</a>.)</p><p>There are important differences in the ability of short and long-acting beta agonists to block these responses.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-acting beta agonists can attenuate the immediate response, but are generally ineffective in preventing or reversing the late response [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/37,38\" class=\"abstract_t\">37,38</a>]. SABAs do not substantially inhibit the inflammatory response.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The long-acting beta agonist, <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a>, can block both the immediate and late phase bronchoconstrictive responses, but not the inflammatory response [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p>As pretreatment with a beta agonist does not block the initiation <span class=\"nowrap\">and/or</span> propagation of airway inflammation by allergen or the resultant increase in bronchial hyperresponsiveness, allergen avoidance is always preferred over pretreatment. (See <a href=\"topic.htm?path=allergen-avoidance-in-the-treatment-of-asthma-and-allergic-rhinitis\" class=\"medical medical_review\">&quot;Allergen avoidance in the treatment of asthma and allergic rhinitis&quot;</a>.) Premedication with either <a href=\"topic.htm?path=cromolyn-sodium-cromoglicate-drug-information\" class=\"drug drug_general\">cromolyn</a> or <a href=\"topic.htm?path=nedocromil-drug-information\" class=\"drug drug_general\">nedocromil</a> sodium would likely prevent the airway inflammation associated with transient allergen exposure; however, the availability of these medications is limited (in the United States, cromolyn is only available in a nebulizer formulation) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"topic.htm?path=the-use-of-chromones-cromoglycates-in-the-treatment-of-asthma#H2\" class=\"medical medical_review\">&quot;The use of chromones (cromoglycates) in the treatment of asthma&quot;, section on 'Limitations on availability'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">USE IN EXERCISE-INDUCED ASTHMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short-acting beta agonists (SABAs) are considered to be the drug of choice for the prevention and treatment of exercise-induced bronchoconstriction (EIB) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/40-42\" class=\"abstract_t\">40-42</a>]. (See <a href=\"topic.htm?path=exercise-induced-bronchoconstriction\" class=\"medical medical_review\">&quot;Exercise-induced bronchoconstriction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H179761390\"><span class=\"h2\">Proposed mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several mechanisms have been proposed to explain how beta agonists inhibit EIB:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The bronchodilation that they induce before exercise may counterbalance the asthma induced by exercise</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The normal bronchodilator response seen within the first few minutes of exercise may be enhanced, thereby overriding or attenuating the airway obstruction that follows exercise</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mediator release associated with EIB may be inhibited due to activation of mast cell beta receptors</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effect of beta agonists on smooth muscle may prevent mediator-induced bronchoconstriction</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta agonists may increase bronchial blood flow, which would reduce the heat loss in the airway that is thought to be one of the mechanisms of EIB [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/43,44\" class=\"abstract_t\">43,44</a>]</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Efficacy of different preparations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The ability of various beta agonists to inhibit or attenuate EIB is dependent upon the minute ventilation (work load) and the particular drug administered. Beta agonists such as <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>, or fenoterol attenuate EIB if taken ten minutes before exercise. The duration of protection varies with the agent used. Albuterol may attenuate EIB for four to six hours [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/45\" class=\"abstract_t\">45</a>], whereas <a href=\"topic.htm?path=metaproterenol-orciprenaline-drug-information\" class=\"drug drug_general\">metaproterenol</a> (no longer available as a metered dose inhaler) may only be protective for two hours [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/46\" class=\"abstract_t\">46</a>].</p><p>The long-acting beta agonists (LABAs), <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a> and <a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">formoterol</a>, are also very effective in attenuating EIB [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/47,48\" class=\"abstract_t\">47,48</a>]. Salmeterol needs to be used at least an hour before exercise, while formoterol can be used 5 to 10 minutes before. As one would expect, their duration of action is longer than the SABAs. As an example, the mean duration of a 50 percent reduction in EIB is 1.5 hours for <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> versus 6.5 hours for formoterol [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/47\" class=\"abstract_t\">47</a>]. Inhaled salmeterol also prevents EIB and produces significant bronchodilation for at least nine hours (<a href=\"image.htm?imageKey=PULM%2F73033%7EPULM%2F81068\" class=\"graphic graphic_figure graphicRef73033 graphicRef81068 \">figure 1A-B</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/48\" class=\"abstract_t\">48</a>]. However, the duration of protection induced by the long-acting preparations may decrease with chronic use (<a href=\"image.htm?imageKey=PULM%2F61821\" class=\"graphic graphic_figure graphicRef61821 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/49\" class=\"abstract_t\">49</a>]. Despite the more prolonged effect of LABAs and FDA approval for use in the prevention of EIB, these agents are not recommended for use as monotherapy for asthma or EIB.</p><p class=\"headingAnchor\" id=\"H179761012\"><span class=\"h1\">LONG-TERM CONTROL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The long-acting beta agonists (LABAs), <a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">formoterol</a>, <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a>, and vilanterol [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/50\" class=\"abstract_t\">50</a>], are used in combination with inhaled glucocorticoids for patients with moderate or severe asthma whose symptoms are inadequately controlled on inhaled glucocorticoid therapy alone, especially when nocturnal symptoms are problematic (<a href=\"image.htm?imageKey=PULM%2F72467\" class=\"graphic graphic_table graphicRef72467 \">table 2</a> and <a href=\"image.htm?imageKey=PULM%2F68143\" class=\"graphic graphic_table graphicRef68143 \">table 6</a> and <a href=\"image.htm?imageKey=PULM%2F57761\" class=\"graphic graphic_table graphicRef57761 \">table 7</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/6\" class=\"abstract_t\">6</a>]. LABAs have additive effects with inhaled glucocorticoids when the two agents are used in combination [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/51-54\" class=\"abstract_t\">51-54</a>]. The use of LABAs to treat moderately severe and severe persistent asthma and the controversy regarding the safety of these medications for chronic maintenance therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-moderate-persistent-asthma-in-adolescents-and-adults\" class=\"medical medical_review\">&quot;Treatment of moderate persistent asthma in adolescents and adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-severe-asthma-in-adolescents-and-adults\" class=\"medical medical_review\">&quot;Treatment of severe asthma in adolescents and adults&quot;</a>.)</p><p>LABAs should never be prescribed as monotherapy for asthma [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/55,56\" class=\"abstract_t\">55,56</a>]. (See <a href=\"topic.htm?path=beta-agonists-in-asthma-controversy-regarding-chronic-use\" class=\"medical medical_review\">&quot;Beta agonists in asthma: Controversy regarding chronic use&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">TOLERANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Decreased sensitivity or tolerance to beta agonists with chronic use (also known as tachyphylaxis) has been identified in laboratory studies and is believed to be primarily mediated by downregulation of beta-2 adrenergic receptors [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/57\" class=\"abstract_t\">57</a>]. However, the clinical importance of this effect is unclear. Most investigators believe that the duration of action of the bronchodilator response is affected more than the peak effect [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2\" class=\"abstract_t\">2</a>], and that oral routes are more likely to induce tolerance than inhaled methods of delivery. Beta-2 adrenergic receptor polymorphisms appear to influence this effect. (See <a href=\"topic.htm?path=beta-2-adrenergic-receptor-dysfunction-and-polymorphism-in-asthma#H4\" class=\"medical medical_review\">&quot;Beta-2 adrenergic receptor dysfunction and polymorphism in asthma&quot;, section on 'Receptor polymorphisms'</a>.)</p><p>In the laboratory, the development of tolerance requires relatively continuous stimulation of the membrane-associated beta receptors. Thus, <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> would theoretically be more likely to produce tolerance than <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a>, which has a shorter duration of action [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/58\" class=\"abstract_t\">58</a>]. However, two randomized trials of the safety and efficacy of albuterol administered on a regular schedule compared to an as-needed regimen in patients with mild asthma failed to demonstrate evidence of tolerance to the acute bronchodilating properties of this beta agonist or an increase in the rate of exacerbations [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/59,60\" class=\"abstract_t\">59,60</a>]. (See <a href=\"topic.htm?path=beta-agonists-in-asthma-controversy-regarding-chronic-use\" class=\"medical medical_review\">&quot;Beta agonists in asthma: Controversy regarding chronic use&quot;</a>.)</p><p>Based on the expectation that longer duration of action (and thus more continuous stimulation of the beta receptors) would increase the development of tolerance, long-acting beta agonists (LABAs; eg, <a href=\"topic.htm?path=formoterol-drug-information\" class=\"drug drug_general\">formoterol</a>, <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a>) would be more likely to induce tolerance than shorter acting agents. However, clinical studies have yielded mixed results. One study found that twelve weeks of regular therapy with salmeterol did not result in a diminution in bronchodilating efficacy or a change in the use of rescue <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> therapy (<a href=\"image.htm?imageKey=PULM%2F78242\" class=\"graphic graphic_figure graphicRef78242 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/61\" class=\"abstract_t\">61</a>]. In contrast, some decrease in the ability of salmeterol to protect against a bronchoconstrictive stimulus has been observed in other reports following a similar duration of salmeterol therapy (<a href=\"image.htm?imageKey=PULM%2F61821\" class=\"graphic graphic_figure graphicRef61821 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/49,62,63\" class=\"abstract_t\">49,62,63</a>]. Chronic use of formoterol has also been shown to reduce the acute bronchodilator response to albuterol following methacholine-induced bronchoconstriction [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/64\" class=\"abstract_t\">64</a>].</p><p>A greater degree of airway inflammation may increase the induction of tolerance to LABAs. Since baseline levels of exhaled nitric oxide (FeNO) may be a surrogate biomarker for the presence of increased airway inflammation [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/65\" class=\"abstract_t\">65</a>], these relationships were examined in study of 26 subjects not on controller therapy for asthma who underwent exercise challenge testing before and after two weeks of <a href=\"topic.htm?path=salmeterol-drug-information\" class=\"drug drug_general\">salmeterol</a> monotherapy [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/66\" class=\"abstract_t\">66</a>]. A 74 &plusmn; 13 percent loss of bronchoprotection was noted among subjects with a FeNO greater than 50 ppb (consistent with eosinophilic airway inflammation), but only a 7 &plusmn; 16 percent gain in bronchoprotection among those with a FeNO less than 25 ppb. This observation lends support to the current practice of avoiding monotherapy with LABAs and suggests that any observed reductions in bronchoprotection with chronic LABA use may be a reflection of the degree of airway inflammation. (See <a href=\"topic.htm?path=exhaled-nitric-oxide-analysis-and-applications\" class=\"medical medical_review\">&quot;Exhaled nitric oxide analysis and applications&quot;</a>.)</p><p>In addition to a potential problem with tolerance, chronic reliance on beta agonist inhalers may disadvantage patients whose disease process involves mechanisms other than bronchial smooth muscle constriction. Without proper recognition and intervention, patients may use more SABA inhalations at progressively more frequent intervals to obtain symptom relief. This overuse has the disadvantages of delaying addition of other therapeutic agents (such as anti-inflammatory drugs) that can reverse or attenuate other important pathophysiologic factors, such as airway edema, mucus secretion, and inflammation.</p><p class=\"headingAnchor\" id=\"H179762302\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beta agonists are associated with several side effects [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/67\" class=\"abstract_t\">67</a>]. Tremor is the most frequent acute side effect and is more noticeable with oral therapy than with inhaled agents. Patient acceptance of tremor is often related to diminished awareness of the tremor due to decreased peak-trough variations over time [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/2,68\" class=\"abstract_t\">2,68</a>]. Increased heart rate and palpitations are dose-dependent and are less common with the selective beta-2 agonists (such as <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>) than with nonselective agents (such as <a href=\"topic.htm?path=metaproterenol-orciprenaline-drug-information\" class=\"drug drug_general\">metaproterenol</a>). Use of a spacer or chamber device reduces these side effects by reducing oral deposition of medication, which contributes to side effects but not bronchodilation.</p><p>Stress-induced (takotsubo) cardiomyopathy has been associated with treatment of status asthmaticus in case reports [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/69-71\" class=\"abstract_t\">69-71</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy#H3\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy&quot;, section on 'Role of catecholamines'</a>.)</p><p>Metabolic disturbances, such as hyperglycemia and hypokalemia, are also reported, although the clinical significance is unclear [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/72-75\" class=\"abstract_t\">72-75</a>]. In some patients, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a> may reduce the incidence of these side effects [<a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/21,23\" class=\"abstract_t\">21,23</a>]. (See <a href=\"topic.htm?path=causes-of-hypokalemia-in-adults#H17666854\" class=\"medical medical_review\">&quot;Causes of hypokalemia in adults&quot;, section on 'Elevated beta-adrenergic activity'</a>.)</p><p class=\"headingAnchor\" id=\"H695278900\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-asthma-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Asthma in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=asthma-in-children-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Asthma in children (The Basics)&quot;</a> and <a href=\"topic.htm?path=asthma-in-adults-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Asthma in adults (The Basics)&quot;</a> and <a href=\"topic.htm?path=medicines-for-asthma-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Medicines for asthma (The Basics)&quot;</a> and <a href=\"topic.htm?path=how-to-use-your-metered-dose-inhaler-adults-the-basics\" class=\"medical medical_basics\">&quot;Patient education: How to use your metered dose inhaler (adults) (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=asthma-treatment-in-adolescents-and-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=trigger-avoidance-in-asthma-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Trigger avoidance in asthma (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=how-to-use-a-peak-flow-meter-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: How to use a peak flow meter (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=asthma-inhaler-techniques-in-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Asthma inhaler techniques in adults (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H7232106\"><span class=\"h2\">Acute exacerbations</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta adrenergic agonists are the most potent and rapidly acting bronchodilator medications available for asthma treatment. Beta agonists interact with beta adrenergic receptors on a variety of cells to relax bronchial smooth muscle, decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The primary use of short-acting beta agonists (SABAs) is the quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness). SABAs (eg, <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a>) are prescribed for use as-needed, rather than on a routine basis. Acute exacerbations of asthma are heterogeneous and the response to therapy is not uniformly predictable. Inhaled and systemic beta-agonist preparations, delivery systems, and dosing guidelines are listed in the tables (<a href=\"image.htm?imageKey=PULM%2F72467\" class=\"graphic graphic_table graphicRef72467 \">table 2</a> and <a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). (See <a href=\"#H3\" class=\"local\">'Use in acute exacerbations of asthma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhaled SABAs (such as <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a>) remain the drug of choice for asthma exacerbations requiring emergency department treatment. Those who can demonstrate proper metered dose inhaler (MDI) technique are initially treated with two to six inhalations of a SABA administered from an MDI using a spacer or chamber device (eg, AeroChamber, InspirEase) (<a href=\"image.htm?imageKey=PULM%2F58957\" class=\"graphic graphic_picture graphicRef58957 \">picture 1</a>). Alternatively, albuterol is administered by nebulizer (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). SABA MDI or nebulizer therapy can be repeated in 30 to 60 minutes until maximal improvement in pulmonary function can be demonstrated. (See <a href=\"#H3\" class=\"local\">'Use in acute exacerbations of asthma'</a> above and <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults#H14\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;, section on 'Inhaled beta agonists'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of acute asthma exacerbations, including severity assessment, monitoring, use of other medications, and disposition, is discussed separately. (See <a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults\" class=\"medical medical_review\">&quot;Management of acute exacerbations of asthma in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If a satisfactory clinical response to MDI administration of a SABA is not achieved or if the exacerbation is severe, a SABA is administered by nebulizer, either as individual treatments every 20 minutes or as a continuous treatment (eg, for more severe exacerbations); the doses are listed in the table (<a href=\"image.htm?imageKey=PULM%2F68683\" class=\"graphic graphic_table graphicRef68683 \">table 1</a>). (See <a href=\"#H2109923\" class=\"local\">'Use in emergency department'</a> above and <a href=\"topic.htm?path=delivery-of-inhaled-medication-in-adults#H10617078\" class=\"medical medical_review\">&quot;Delivery of inhaled medication in adults&quot;, section on 'Continuous nebulization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rarely, <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> (0.01 <span class=\"nowrap\">mg/kg</span> to a maximum dose of 0.3 mg) is administered subcutaneously or intramuscularly to treat acute asthma exacerbations and is reserved for times when nebulized therapy is either unavailable or ineffective clinically. (See <a href=\"#H3\" class=\"local\">'Use in acute exacerbations of asthma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Until the results of additional comparison trials with racemic <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> have been published, <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">levalbuterol</a> use should be reserved for those patients who have a known history of adverse effects from albuterol. (See <a href=\"#H5\" class=\"local\">'Levalbuterol'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H7232095\"><span class=\"h2\">Prevention of exacerbations and long-term control</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Despite the ability of beta agonists to prevent or attenuate allergen-induced bronchoconstriction, avoidance of allergen exposure by sensitized patients is always preferred over pretreatment with a SABA. Pretreatment does not block the airway inflammation and resultant increase in bronchial hyperresponsiveness associated with allergen exposure. (See <a href=\"#H7\" class=\"local\">'Prophylaxis in allergen-induced asthma'</a> above and <a href=\"topic.htm?path=allergen-avoidance-in-the-treatment-of-asthma-and-allergic-rhinitis\" class=\"medical medical_review\">&quot;Allergen avoidance in the treatment of asthma and allergic rhinitis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-acting beta agonists (SABAs) are considered to be the drug of choice for the prevention and treatment of exercise-induced bronchoconstriction. (See <a href=\"#H8\" class=\"local\">'Use in exercise-induced asthma'</a> above and <a href=\"topic.htm?path=exercise-induced-bronchoconstriction#H10\" class=\"medical medical_review\">&quot;Exercise-induced bronchoconstriction&quot;, section on 'Selection of pharmacologic therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long-acting beta agonists (LABAs) are used in combination with inhaled glucocorticoids for patients with moderate or severe asthma whose symptoms are inadequately controlled with inhaled glucocorticoid therapy. LABAs should never be prescribed as monotherapy. The controversy regarding long-term use of beta agonists is discussed separately. (See <a href=\"#H179761012\" class=\"local\">'Long-term control'</a> above and <a href=\"topic.htm?path=beta-agonists-in-asthma-controversy-regarding-chronic-use\" class=\"medical medical_review\">&quot;Beta agonists in asthma: Controversy regarding chronic use&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7232126\"><span class=\"h2\">Tolerance and toxicity</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased sensitivity or tolerance to beta agonists is a potential effect that may occur with chronic, continuous use of beta agonists. The effect appears primarily mediated by downregulation of beta-2 adrenergic receptors, such that increasing agonist doses are required for the same degree of bronchodilation. The clinical significance of tolerance largely relates to patients who overuse beta agonist inhalers, rather than appropriately avoiding the relevant exposure (eg, allergen) or adding appropriate anti-inflammatory controller medication. (See <a href=\"#H12\" class=\"local\">'Tolerance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The potential role of adrenergic receptor polymorphisms in development of tolerance is discussed separately. (See <a href=\"topic.htm?path=beta-2-adrenergic-receptor-dysfunction-and-polymorphism-in-asthma#H4\" class=\"medical medical_review\">&quot;Beta-2 adrenergic receptor dysfunction and polymorphism in asthma&quot;, section on 'Receptor polymorphisms'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tremor is the most frequent acute side effect associated with beta agonists. Other side effects include palpitations, tachycardia, metabolic disturbances, and rarely stress-induced (takotsubo) cardiomyopathy. (See <a href=\"#H179762302\" class=\"local\">'Toxicity'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/1\" class=\"nounderline abstract_t\">Cazzola M, Page CP, Rogliani P, Matera MG. &beta;2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187:690.</a></li><li class=\"breakAll\">Sorkness CA. Beta-adrenergic Agonists. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1485-503.</li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/3\" class=\"nounderline abstract_t\">Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev 2001; 2:57.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/4\" class=\"nounderline abstract_t\">Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18.</a></li><li class=\"breakAll\">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on May 31, 2016).</li><li class=\"breakAll\">Global Initiative for Asthma. 2017 GINA report: Global strategy for asthma management and prevention. www.ginasthma.org (Accessed on June 01, 2017).</li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/7\" class=\"nounderline abstract_t\">Tipton WR, Nelson HS. Frequent parenteral terbutaline in the treatment of status asthmaticus in children. Ann Allergy 1987; 58:252.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/8\" class=\"nounderline abstract_t\">Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83:513.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/9\" class=\"nounderline abstract_t\">Colacone A, Afilalo M, Wolkove N, Kreisman H. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest 1993; 104:835.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/10\" class=\"nounderline abstract_t\">Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103:665.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/11\" class=\"nounderline abstract_t\">Wolfe JD, Yamate M, Biedermann AA, Chu TJ. Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. JAMA 1985; 253:2068.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/12\" class=\"nounderline abstract_t\">Fanta CH, Rossing TH, McFadden ER Jr. Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated? Am J Med 1986; 80:5.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/13\" class=\"nounderline abstract_t\">Appel D, Karpel JP, Sherman M. Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate. J Allergy Clin Immunol 1989; 84:90.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/14\" class=\"nounderline abstract_t\">Williams S, Seaton A. Intravenous or inhaled salbutamol in severe acute asthma? Thorax 1977; 32:555.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/15\" class=\"nounderline abstract_t\">Pierce RJ, Payne CR, Williams SJ, et al. Comparison of intravenous and inhaled terbutaline in the treatment of asthma. Chest 1981; 79:506.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/16\" class=\"nounderline abstract_t\">Salmeron S, Brochard L, Mal H, et al. Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. Am J Respir Crit Care Med 1994; 149:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/17\" class=\"nounderline abstract_t\">Travers AH, Rowe BH, Barker S, et al. The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. Chest 2002; 122:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/18\" class=\"nounderline abstract_t\">Travers A, Jones AP, Kelly K, et al. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev 2001; :CD002988.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/19\" class=\"nounderline abstract_t\">Maguire JF, O'Rourke PP, Colan SD, et al. Cardiotoxicity during treatment of severe childhood asthma. Pediatrics 1991; 88:1180.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/20\" class=\"nounderline abstract_t\">Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001; 108:681.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/21\" class=\"nounderline abstract_t\">Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/22\" class=\"nounderline abstract_t\">&quot;Pharmaceutical Approvals Monthly&quot; FDC Reports. Chevy Chase, MD. 2005; 10(3):11.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/23\" class=\"nounderline abstract_t\">Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/24\" class=\"nounderline abstract_t\">Tripp K, McVicar WK, Nair P, et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. J Allergy Clin Immunol 2008; 122:544.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/25\" class=\"nounderline abstract_t\">Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/26\" class=\"nounderline abstract_t\">L&ouml;tvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/27\" class=\"nounderline abstract_t\">Levalbuterol for asthma. Med Lett Drugs Ther 1999; 41:51.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/28\" class=\"nounderline abstract_t\">Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124:844.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/29\" class=\"nounderline abstract_t\">Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/30\" class=\"nounderline abstract_t\">Hamilos DL, D'Urzo A, Levy RJ, et al. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol 2007; 99:540.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/31\" class=\"nounderline abstract_t\">Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/32\" class=\"nounderline abstract_t\">Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123:128.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/33\" class=\"nounderline abstract_t\">Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/34\" class=\"nounderline abstract_t\">Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004; 113:503.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/35\" class=\"nounderline abstract_t\">Grembiale RD, Pelaia G, Naty S, et al. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther 2002; 15:463.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/36\" class=\"nounderline abstract_t\">Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164:923.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/37\" class=\"nounderline abstract_t\">Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79:734.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/38\" class=\"nounderline abstract_t\">Howarth PH, Durham SR, Lee TH, et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132:986.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/39\" class=\"nounderline abstract_t\">Twentyman OP, Finnerty JP, Harris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336:1338.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/40\" class=\"nounderline abstract_t\">Bundgaard A, Buch D, Schmidt A, Bach-Mortensen N. Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder. Eur J Respir Dis Suppl 1983; 130:36.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/41\" class=\"nounderline abstract_t\">Rohr AS, Siegel SC, Katz RM, et al. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. Ann Allergy 1987; 59:107.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/42\" class=\"nounderline abstract_t\">Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol 1989; 83:882.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/43\" class=\"nounderline abstract_t\">McFadden ER Jr. Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet 1990; 335:880.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/44\" class=\"nounderline abstract_t\">Anderson SD, Daviskas E. The airway microvasculature and exercise induced asthma. Thorax 1992; 47:748.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/45\" class=\"nounderline abstract_t\">Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/46\" class=\"nounderline abstract_t\">Sly RM, Heimlich EM, Ginsburg J, et al. Exercise-induced bronchospasm: evaluation of metaproterenol. Ann Allergy 1968; 26:253.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/47\" class=\"nounderline abstract_t\">Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992; 89:1176.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/48\" class=\"nounderline abstract_t\">Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/49\" class=\"nounderline abstract_t\">Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/50\" class=\"nounderline abstract_t\">Dwan K, Milan SJ, Bax L, et al. Vilanterol and fluticasone furoate for asthma. Cochrane Database Syst Rev 2016; 9:CD010758.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/51\" class=\"nounderline abstract_t\">Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; :CD005533.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/52\" class=\"nounderline abstract_t\">Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; :CD005535.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/53\" class=\"nounderline abstract_t\">O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/54\" class=\"nounderline abstract_t\">Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/55\" class=\"nounderline abstract_t\">Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/56\" class=\"nounderline abstract_t\">Lemanske RF Jr, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010; 126:449.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/57\" class=\"nounderline abstract_t\">Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4:2881.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/58\" class=\"nounderline abstract_t\">Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984; 85:34.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/59\" class=\"nounderline abstract_t\">Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/60\" class=\"nounderline abstract_t\">Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355:1675.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/61\" class=\"nounderline abstract_t\">Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/62\" class=\"nounderline abstract_t\">Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/63\" class=\"nounderline abstract_t\">Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342:833.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/64\" class=\"nounderline abstract_t\">Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005; 99:566.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/65\" class=\"nounderline abstract_t\">Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/66\" class=\"nounderline abstract_t\">Bonini M, Permaul P, Kulkarni T, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med 2013; 188:1407.</a></li><li class=\"breakAll\">Nelson HS. Beta-adrenergic agonists. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St Louis 2003. p.803.</li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/68\" class=\"nounderline abstract_t\">Jenne JW, Valcarenghi G, Druz WS, et al. Comparison of tremor responses to orally administered albuterol and terbutaline. Am Rev Respir Dis 1986; 134:708.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/69\" class=\"nounderline abstract_t\">Kurisu S, Inoue I, Kawagoe T, et al. Assessment of medications in patients with tako-tsubo cardiomyopathy. Int J Cardiol 2009; 134:e120.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/70\" class=\"nounderline abstract_t\">Osuorji I, Williams C, Hessney J, et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009; 102:301.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/71\" class=\"nounderline abstract_t\">Rennyson SL, Parker JM, Symanski JD, Littmann L. Recurrent, severe, and rapidly reversible apical ballooning syndrome in status asthmaticus. Heart Lung 2010; 39:537.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/72\" class=\"nounderline abstract_t\">Leslie D, Coats PM. Salbutamol-induced diabetic ketoacidosis. Br Med J 1977; 2:768.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/73\" class=\"nounderline abstract_t\">van den Berg BT, Louwerse RT, Luiken GJ, et al. Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol. Clin Drug Investig 1998; 15:523.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/74\" class=\"nounderline abstract_t\">Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 97:24.</a></li><li><a href=\"https://www.uptodate.com/contents/beta-agonists-in-asthma-acute-administration-and-prophylactic-use/abstract/75\" class=\"nounderline abstract_t\">Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55:650.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 558 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">USE IN ACUTE EXACERBATIONS OF ASTHMA</a><ul><li><a href=\"#H2109930\" id=\"outline-link-H2109930\">Heterogeneity of response</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Importance of route of delivery</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Levalbuterol</a></li><li><a href=\"#H1487481\" id=\"outline-link-H1487481\">Use as rescue medication</a></li><li><a href=\"#H2109923\" id=\"outline-link-H2109923\">Use in emergency department</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PROPHYLAXIS IN ALLERGEN-INDUCED ASTHMA</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">USE IN EXERCISE-INDUCED ASTHMA</a><ul><li><a href=\"#H179761390\" id=\"outline-link-H179761390\">Proposed mechanisms</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Efficacy of different preparations</a></li></ul></li><li><a href=\"#H179761012\" id=\"outline-link-H179761012\">LONG-TERM CONTROL</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">TOLERANCE</a></li><li><a href=\"#H179762302\" id=\"outline-link-H179762302\">TOXICITY</a></li><li><a href=\"#H695278900\" id=\"outline-link-H695278900\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H13\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H7232106\" id=\"outline-link-H7232106\">Acute exacerbations</a></li><li><a href=\"#H7232095\" id=\"outline-link-H7232095\">Prevention of exacerbations and long-term control</a></li><li><a href=\"#H7232126\" id=\"outline-link-H7232126\">Tolerance and toxicity</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/558|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/73033\" class=\"graphic graphic_figure\">- Long acting beta agonist in EIB</a></li><li><a href=\"image.htm?imageKey=PULM/81068\" class=\"graphic graphic_figure\">- Beta agonist effect in EIB</a></li><li><a href=\"image.htm?imageKey=PULM/61821\" class=\"graphic graphic_figure\">- Attenuation of beta agonist effect in EIB</a></li><li><a href=\"image.htm?imageKey=PULM/78242\" class=\"graphic graphic_figure\">- Persistence of beta agonist effect over time</a></li></ul></li><li><div id=\"PULM/558|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/58957\" class=\"graphic graphic_picture\">- MDI spacers</a></li></ul></li><li><div id=\"PULM/558|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/68683\" class=\"graphic graphic_table\">- Doses of beta agonists for asthma exacerbations</a></li><li><a href=\"image.htm?imageKey=PULM/72467\" class=\"graphic graphic_table\">- Doses beta agonist preparations</a></li><li><a href=\"image.htm?imageKey=PULM/53233\" class=\"graphic graphic_table\">- Adjusting Rx 12 and up</a></li><li><a href=\"image.htm?imageKey=PULM/78322\" class=\"graphic graphic_table\">- Adjusting Rx 0 to 4 years</a></li><li><a href=\"image.htm?imageKey=PULM/64986\" class=\"graphic graphic_table\">- Adjusting Rx 5 to 11 years</a></li><li><a href=\"image.htm?imageKey=PULM/68143\" class=\"graphic graphic_table\">- Usual doses inhaled GC-LABA</a></li><li><a href=\"image.htm?imageKey=PULM/57761\" class=\"graphic graphic_table\">- Doses asthma control meds other than ICS for kids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=allergen-avoidance-in-the-treatment-of-asthma-and-allergic-rhinitis\" class=\"medical medical_review\">Allergen avoidance in the treatment of asthma and allergic rhinitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=an-overview-of-asthma-management\" class=\"medical medical_review\">An overview of asthma management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=beta-agonists-in-asthma-controversy-regarding-chronic-use\" class=\"medical medical_review\">Beta agonists in asthma: Controversy regarding chronic use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=beta-2-adrenergic-receptor-dysfunction-and-polymorphism-in-asthma\" class=\"medical medical_review\">Beta-2 adrenergic receptor dysfunction and polymorphism in asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hypokalemia-in-adults\" class=\"medical medical_review\">Causes of hypokalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-stress-takotsubo-cardiomyopathy\" class=\"medical medical_review\">Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=delivery-of-inhaled-medication-in-adults\" class=\"medical medical_review\">Delivery of inhaled medication in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=delivery-of-inhaled-medication-in-children\" class=\"medical medical_review\">Delivery of inhaled medication in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exercise-induced-bronchoconstriction\" class=\"medical medical_review\">Exercise-induced bronchoconstriction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exhaled-nitric-oxide-analysis-and-applications\" class=\"medical medical_review\">Exhaled nitric oxide analysis and applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-exacerbations-of-asthma-in-adults\" class=\"medical medical_review\">Management of acute exacerbations of asthma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-asthma\" class=\"medical medical_review\">Pathogenesis of asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=asthma-in-adults-the-basics\" class=\"medical medical_basics\">Patient education: Asthma in adults (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=asthma-in-children-the-basics\" class=\"medical medical_basics\">Patient education: Asthma in children (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=asthma-inhaler-techniques-in-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Asthma inhaler techniques in adults (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=asthma-treatment-in-adolescents-and-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=how-to-use-a-peak-flow-meter-beyond-the-basics\" class=\"medical medical_patient\">Patient education: How to use a peak flow meter (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=how-to-use-your-metered-dose-inhaler-adults-the-basics\" class=\"medical medical_basics\">Patient education: How to use your metered dose inhaler (adults) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medicines-for-asthma-the-basics\" class=\"medical medical_basics\">Patient education: Medicines for asthma (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=trigger-avoidance-in-asthma-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Trigger avoidance in asthma (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">Pulse oximetry</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-asthma-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Asthma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-use-of-chromones-cromoglycates-in-the-treatment-of-asthma\" class=\"medical medical_review\">The use of chromones (cromoglycates) in the treatment of asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-use-of-inhaler-devices-in-adults\" class=\"medical medical_review\">The use of inhaler devices in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-use-of-inhaler-devices-in-children\" class=\"medical medical_review\">The use of inhaler devices in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-moderate-persistent-asthma-in-adolescents-and-adults\" class=\"medical medical_review\">Treatment of moderate persistent asthma in adolescents and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-severe-asthma-in-adolescents-and-adults\" class=\"medical medical_review\">Treatment of severe asthma in adolescents and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-medication-nebulizers-in-children\" class=\"medical medical_review\">Use of medication nebulizers in children</a></li></ul></div></div>","javascript":null}